| Literature DB >> 31193619 |
Selma Ben Mustapha1, Paul Meijnders2, Nicolas Jansen1, Ferenc Lakosi3, Philippe Coucke1.
Abstract
AIM: To provide an overview of Radiation Oncology (RO) teaching to medical students around Europe.Entities:
Keywords: Curriculum; Medical students; Radiation oncology; Undergraduate medical education
Year: 2019 PMID: 31193619 PMCID: PMC6538841 DOI: 10.1016/j.ctro.2019.04.010
Source DB: PubMed Journal: Clin Transl Radiat Oncol ISSN: 2405-6308
Number of respondents per country and country codes.
| Country | # of respondents |
|---|---|
| Belgium (BE) | 4 |
| Bulgaria (BG) | 1 |
| Czech Republic (CZ) | 1 |
| Croatia (HR) | 1 |
| Denmark (DK) | 2 |
| Hungary (H) | 1 |
| France (FR) | 1 |
| Germany (DE) | 2 |
| Italy (IT) | 4 |
| Netherland (NL) | 2 |
| Norway (NO) | 1 |
| Poland (PL) | 1 |
| Portugal (PT) | 1 |
| Romania (RO) | 1 |
| Serbia (RS) | 1 |
| Slovakia (SK) | 3 |
| Slovenia (SI) | 1 |
| Spain (SP) | 2 |
| Switzerland (CH) | 2 |
| Total: 19 countries | 32 respondents |
Fig. 1Number of hours of teaching devoted to RO (RO hrs) in deep blue and the number of hours devoted to the teaching of medical oncology for each respondent institution (ONC hrs) in light blue.
Fig. 2Percentage of institutions in which each key topic in RO was taught to medical students during their core curriculum.
Final assessment of knowledge for each key topic in RO: the total number of respondents for each topic is detailed in the table. For Each topic the number of institutions using a certain method is expressed as an absolute number and in percentage. Abbreviation used in the table: N: No examination; W: Written examination, CBE: Computer based Examination; OSCE: Objective Structured Clinical Examination.
| Topics | N | O | W | OSCE | CBE | Number of respondents |
|---|---|---|---|---|---|---|
| Radiobiology | 5 (16,66%) | 7 (23,33%) | 14 (46,66%) | 1 (3,33%) | 3 (10%) | 30 |
| Radiation physics | 5 (20,83%) | 4 (16,66%) | 11 (45,83%) | 1 (4,16%) | 3 (12,5%) | 24 |
| Radiosurgery | 5 (20%) | 8 (32%) | 9 (36%) | 0 (0%) | 3 (12%) | 25 |
| Brachytherapy | 3 (11,53%) | 10 (38,46%) | 10 (38,46%) | 0 (0%) | 3 (11,5″%) | 26 |
| Palliative RT | 2 (7,4%) | 10 (37,03%) | 11 (40,74%) | 2 (7,40%) | 2 (7,40%) | 27 |
| Breast RT | 3 (10%) | 10 (33,33%) | 12 (40%) | 2 (6,66%) | 3 (10%) | 30 |
| CNS RT | 2 (7,69%) | 8 (30,76%) | 11 (42,30%) | 2 (7,69%) | 3 (11,53%) | 26 |
| Head and neck RT | 3 (10,71%) | 9 (32,14%) | 11 (39,28%) | 2 (7,14%) | 3 (10,71%) | 28 |
| Lung RT | 2 (6,89%) | 9 (31,03%) | 13 (44,82%) | 2 (6,89%) | 3 (10,34%) | 29 |
| Gastro-intestinal RT | 2 (7,4%) | 9 (33,33%) | 11 (40,74%) | 2 (7,'%) | 3 (11,11%) | 27 |
| Genito-urinary RT | 2 (7,14%) | 9 (32,14%) | 12 (42,85%) | 2 (7,14%) | 3 (10,71%) | 28 |
| Gynaecologic RT | 3 (10,34%) | 10 (34,48%) | 11 (37,93%) | 2 (6,89%) | 3 (10,34%) | 29 |
| Skin RT | 6 (28,57%) | 5 (23,80%) | 8 (38,09%) | 1 (4,76%) | 1 (4,76%) | 21 |
| Bone and soft tissue RT | 5 (26,31%) | 7 (36,84%) | 6 (31,57%) | 0 (0%) | 1 (5,26%) | 19 |
| Benign conditions RT | 7 (53,84%) | 2 (15,38%) | 3 (23,07%) | 0 (0%) | 1 (7,69%) | 13 |
| Pediatric RT | 8 (50%) | 1 (6,25%) | 5 (31,25%) | 0 (0%) | 2 (12,5%) | 16 |
| Toxicities of RT | 4 (15,38%) | 7 (26,92%) | 11 (42,30%) | 2 (7,69%) | 2 (7,69%) | 26 |
| Toxicities management | 5 (25%) | 6 (30%) | 6 (30%) | 1 (5%) | 2 (10%) | 20 |
| RT for Hematologic malignancies | 7 (36,84%) | 4 (21,05%) | 4 (21,05%) | 1 (5,26%) | 3 (15,78%) | 19 |
| Economic aspects of RT | 8 (72,72%) | 1 (9,09%) | 1 (9,09%) | 0 (0%) | 1 (9,09%) | 11 |
| Radiation protection | 5 (31,25%) | 4 (25%) | 5 (31,25%) | 0 (0%) | 2 (12,5%) | 16 |